

## **Mass Balance Studies**

### **Metabolite profiling of <sup>14</sup>C-omacetaxine mepesuccinate in plasma and excreta of cancer patients**

Xenobiotica. 2016 Mar 21;1-11. [Epub ahead of print]

Nijenhuis CM, Lucas L, Rosing H, Robertson P Jr, Hellriegel ET, Schellens JH, Beijnen JH.

[Link to PubMed](#)

### **Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas**

Invest New Drugs. 2015 Feb;33(1):233-40. doi: 10.1007/s10637-014-0181-7. Epub 2014 Nov 8.

Dubbelman AC, Rosing H, Nijenhuis C, Huitema AD, Mergui-Roelvink M, Gupta A, Verbel D, Thompson G, Shumaker R, Schellens JH, Beijnen JH.

[Link to PubMed](#)

### **Pharmacokinetics and excretion of <sup>14</sup>C-bendamustine in patients with relapsed or refractory malignancy**

Drugs R D. 2013 Mar;13(1):17-28. doi: 10.1007/s40268-012-0001-5.

Dubbelman AC, Rosing H, Darwish M, D'Andrea D, Bond M, Hellriegel E, Robertson P Jr, Beijnen JH, Schellens JH.

[Link to PubMed](#)

### **Disposition and metabolism of <sup>14</sup>C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors**

Cancer Chemother Pharmacol. 2012 Nov;70(5):653-63. doi: 10.1007/s00280-012-1947-2. Epub 2012 Aug 22.

Dubbelman AC, Uthagrove A, Beijnen JH, Marchetti S, Tan E, Krone K, Anand S, Schellens JH.

[Link to PubMed](#)

### **Mass balance study of [<sup>14</sup>C]eribulin in patients with advanced solid tumors**

Drug Metab Dispos. 2012 Feb;40(2):313-21. doi: 10.1124/dmd.111.042762. Epub 2011 Oct 31.

Dubbelman AC, Rosing H, Jansen RS, Mergui-Roelvink M, Huitema AD, Koetz B, Lymboura M, Reyderman L, Lopez-Anaya A, Schellens JH, Beijnen JH.

[Link to PubMed](#)

### **Bioanalytical aspects of clinical mass balance studies in oncology**

Bioanalysis. 2011 Dec;3(23):2637-55. doi: 10.4155/bio.11.276.

Dubbelman AC, Rosing H, Schellens JH, Beijnen JH.

[Link to PubMed](#)

### **Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer**

Invest New Drugs. 2005 Oct;23(5):429-36.

Beumer JH, Rademaker-Lakhai JM, Rosing H, Lopez-Lazaro L, Beijnen JH, Schellens JH.

[Link to PubMed](#)

## **Bioanalytical Support of Clinical Studies**

### **Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study**

Cancer. 2016 Mar 11. doi: 10.1002/cncr.29864. [Epub ahead of print]

Meulendijks D, de Groot JW, Los M, Boers JE, Beerepoot LV, Polee MB, Beeker A, Portielje JE, Goey SH, de Jong RS, Vanhoutvin SA, Kuiper M, Sikorska K, Pluim D, Beijnen JH, Schellens JH, Grootsholten C, Tesselaar ME, Cats A.

[Link to PubMed](#)

### **Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care**

Eur J Cancer. 2016 Feb;54:120-30. doi: 10.1016/j.ejca.2015.10.013. Epub 2016 Jan 4.

Meulendijks D, van Hasselt JG, Huitema AD, van Tinteren H, Deenen MJ, Beijnen JH, Cats A, Schellens JH.

[Link to PubMed](#)

### **Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer**

Cancers (Basel). 2016 Jan 2;8(1). pii: E6. doi: 10.3390/cancers8010006.

Crombag MR, Joerger M, Thürlimann B, Schellens JH, Beijnen JH, Huitema AD.

[Link to PubMed](#)

### **Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study**

Invest New Drugs. 2016 Feb;34(1):119-28. doi: 10.1007/s10637-015-0309-4. Epub 2015 Dec 8.  
Meulendijks D, Beerepoot LV, Boot H, de Groot JW, Los M, Boers JE, Vanhoutvin SA, Polee MB, Beeker A,  
Portielje JE, de Jong RS, Goey SH, Kuiper M, Sikorska K, Beijnen JH, Tesselaar ME, Schellens JH, Cats A.  
[Link to PubMed](#)

**Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer**

AAPS J. 2016 Mar;18(2):362-71. doi: 10.1208/s12248-015-9838-1. Epub 2015 Nov 24.

Yu H, Hendriks JJ, Rottenberg S, Schellens JH, Beijnen JH, Huitema AD.

[Link to PubMed](#)

**P-glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain Disposition and Oral Availability of the Novel Taxane Cabazitaxel (Jevtana) in Mice**

Mol Pharm. 2015 Oct 5;12(10):3714-23. doi: 10.1021/acs.molpharmaceut.5b00470. Epub 2015 Sep 15.

Tang SC, Kort A, Cheung KL, Rosing H, Fukami T, Durmus S, Wagenaar E, Hendriks JJ, Nakajima M, van Vlijmen BJ, Beijnen JH, Schinkel AH.

[Link to PubMed](#)

**Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model**

Int J Cancer. 2016 Feb 1;138(3):758-69. doi: 10.1002/ijc.29812. Epub 2015 Sep 21.

Hendriks JJ, Lagas JS, Song JY, Rosing H, Schellens JH5, Beijnen JH, Rottenberg S, Schinkel AH.

[Link to PubMed](#)

**Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer**

Br J Cancer. 2015 Jul 28;113(3):396-402. doi: 10.1038/bjc.2015.256. Epub 2015 Jul 16.

van der Noll R, Marchetti S, Steeghs N, Beijnen JH, Mergui-Roelvink MW, Harms E, Rehorst H, Sonke GS, Schellens JH.

[Link to PubMed](#)

**Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen**

Biomed Res Int. 2015 Aug;54(8):797-810. doi: 10.1007/s40262-015-0273-3.

de Vries Schultink AH, Zwart W, Linn SC, Beijnen JH, Huitema AD.

[Link to PubMed](#)

**Variability in bioavailability of small molecular tyrosine kinase inhibitors**

Cancer Treat Rev. 2015 May;41(5):412-22. doi: 10.1016/j.ctrv.2015.03.005. Epub 2015 Mar 20.

Herbrink M, Nuijen B, Schellens JH, Beijnen JH.

[Link to PubMed](#)

**Concentrations of Erlotinib in Tumor Tissue and Plasma in Non-Small-Cell Lung Cancer Patients After Neoadjuvant Therapy**

Clin Lung Cancer. 2015 Jul;16(4):320-4. doi: 10.1016/j.clc.2014.12.012. Epub 2014 Dec 31.

Lankheet NA, Schaake EE, Burgers SA, van Pel R, Beijnen JH, Huitema AD, Klomp H; NEL Study Group.

[Link to PubMed](#)

**Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1)**

Pharm Res. 2015 Jul;32(7):2205-16. doi: 10.1007/s11095-014-1609-7. Epub 2015 Jan 8.

Kort A, Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.

[Link to PubMed](#)

**Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662**

Br J Clin Pharmacol. 2015 May;79(5):809-19. doi: 10.1111/bcp.12550.

Yu H, Steeghs N, Kloth JS, de Wit D, van Hasselt JG, van Erp NP, Beijnen JH, Schellens JH, Mathijssen RH, Huitema AD.

[Link to PubMed](#)

**Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer**

Invest New Drugs. 2015 Dec;33(6):1197-205. doi: 10.1007/s10637-015-0281-z. Epub 2015 Sep 11.

van der Noll R, Smit WM, Wymenga AN, Boss DS, Grob M, Huitema AD, Rosing H, Tibben MM, Keessen M, Rehorst H, Beijnen JH, Schellens JH.

[Link to PubMed](#)

**Lysophospholipids secreted by splenic macrophages induce chemotherapy resistance via interference with the DNA damage response**

Nat Commun. 2014 Nov 12;5:5275. doi: 10.1038/ncomms6275.

Houthuijzen JM, Daenen LG, Roodhart JM, Oosterom I, van Jaarsveld MT, Govaert KM, Smith ME, Sadatmand SJ, Rosing H, Kruse F, Helms BJ, van Rooijen N, Beijnen JH, Haribabu B, van de Lest CH, Voest EE.

[Link to PubMed](#)

## **Bioanalytical Method Development, Validation and Application**

**Development and clinical validation of an LC-MS/MS method for the quantification of pazopanib in DBS**

Bioanalysis. 2016 Jan;8(2):123-34. doi: 10.4155/bio.15.235. Epub 2015 Dec 10.

Verheijen RB, Bins S, Thijssen B, Rosing H, Nan L, Schellens JH, Mathijssen RH, Lolkema MP, Beijnen JH, Steeghs N, Huitema AD.

[Link to PubMed](#)

**Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses**

Pharmacol Res Perspect. 2015 Mar;3(2):e00131. doi: 10.1002/prp2.131. Epub 2015 Mar 25.

Keizer RJ, Jansen RS, Rosing H, Thijssen B, Beijnen JH, Schellens JH, Huitema AD.

[Link to PubMed](#)

**Dried Blood Spot Self-Sampling at Home for the Individualization of Tamoxifen Treatment: A Feasibility Study**

Ther Drug Monit. 2015 Dec;37(6):833-6. doi: 10.1097/FTD.0000000000000224.

Jager NG, Rosing H, Linn SC, Schellens JH, Beijnen JH.

[Link to PubMed](#)

**Development of an LC-MS/MS assay for the quantitative determination of the intracellular 5-fluorouracil nucleotides responsible for the anticancer effect of 5-fluorouracil**

J Pharm Biomed Anal. 2015 Jun 10;110:58-66. doi: 10.1016/j.jpba.2015.02.051. Epub 2015 Mar 10.

Derissen EJ, Hillebrand MJ, Rosing H, Schellens JH, Beijnen JH.

[Link to PubMed](#)

**Validation of high-performance liquid chromatography-tandem mass spectrometry assays quantifying omacetaxine mepesuccinate and its 4' des-methyl and cephalotaxine metabolites in human plasma and urine**

J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Oct 1;1002:152-9. doi: 10.1016/j.jchromb.2015.08.015.

Epub 2015 Aug 18.

Nijenhuis CM, Lucas L, Rosing H, Schellens JH, Beijnen JH, Gorman SH, Burke SM, Campbell DA, Chapple MW, Yousey TH, Mulvana DE.

[Link to PubMed](#)

**Quantifying vemurafenib in dried blood spots using high-performance LC-MS/MS**

Bioanalysis. 2014;6(23):3215-24. doi: 10.4155/bio.14.171.

Nijenhuis CM, Rosing H, Schellens JH, Beijnen JH.

[Link to PubMed](#)

**Determination of tamoxifen and endoxifen in dried blood spots using LC-MS/MS and the effect of coated DBS cards on recovery and matrix effects**

Bioanalysis. 2014;6(22):2999-3009. doi: 10.4155/bio.14.157.

Jager NG, Rosing H, Schellens JH, Beijnen JH.

[Link to PubMed](#)

**Procedures and practices for the validation of bioanalytical methods using dried blood spots: a review**

Bioanalysis. 2014 Sep;6(18):2481-514. doi: 10.4155/bio.14.185.

Jager NG, Rosing H, Schellens JH, Beijnen JH.

[Link to PubMed](#)

**Quantification of taxanes in biological matrices: a review of bioanalytical assays and recommendations for development of new assays**

Bioanalysis. 2014 Apr;6(7):993-1010. doi: 10.4155/bio.14.48.

Hendriks JJ, Rosing H, Schinkel AH, Schellens JH, Beijnen JH.

[Link to PubMed](#)